Table 3: (a) Cost categories breakdown per patient per visit (PPPV) by demographic characteristics, IV drug, and number of drugs administered per visit1. (b) Cost categories breakdown per patient per month (PPPM) by demographic characteristics, IV drug, and number of drugs administered per visit1.
(a)

CategoryNo. of patientsNo. of visits TotalIV drugIV administrationOther visit-related services
Average costs ($)%Average costs ($)%Average costs ($)%Average costs ($)%

Total1,22813,5832,427.33100.0%1,449.8559.7%399.4216.5%578.0623.8%
Age
 Less than 251171,9441,117.32100.0%462.6041.4%314.5328.1%340.1930.4%
 25 to 391522,0012,228.42100.0%1,276.2857.3%447.0720.1%505.0722.7%
 40 to 543163,4712,632.44100.0%1,531.8158.2%435.1016.5%665.5225.3%
 55 to 643453,3513,292.29100.0%2,057.0962.5%457.1413.9%778.0623.6%
 Greater than 642982,8162,190.91100.0%1,431.0965.3%311.4914.2%448.3320.5%
Gender2
 Female2893,3672,149.91100.0%1,282.0559.6%341.7015.9%526.1624.5%
 Male2953,6172,082.48100.0%1,162.3555.8%360.5717.3%559.5626.9%
Region
 Midwest2402,6532,471.90100.0%1,485.4560.1%424.7617.2%561.6922.7%
 Northeast413422,240.14100.0%1,348.4460.2%391.3117.5%500.3922.3%
 South6107,1122,140.51100.0%1,166.5054.5%373.6817.5%600.3328.0%
 Southwest1071,0641,675.80100.0%1,026.8561.3%308.4018.4%340.5620.3%
 West2302,4123,582.08100.0%2,447.1468.3%488.7513.6%646.1918.0%
Insurance type3
 Managed care6226,8742,936.17100.0%1,783.8660.8%504.2217.2%648.1022.1%
 Medicare2832,7631,879.52100.0%1,182.8062.9%271.8414.5%424.8822.6%
 Medicare HMO242511,543.22100.0%880.7057.1%241.5115.6%421.0127.3%
 Medicaid67787859.31100.0%344.7440.1%91.6110.7%422.9649.2%
 Medicaid HMO10145709.35100.0%334.7147.2%185.9426.2%188.7026.6%
 Indemnity681,0362,199.25100.0%1,359.2261.8%371.2416.9%468.8021.3%
 Other41541,7272,402.50100.0%1,281.9853.4%384.4116.0%736.1130.6%
IV drug (for mSTS)5
 Gemcitabine-based4293,3153,302.95100.0%2,447.1674.1%358.7010.9%497.0915.0%
 Anthracycline-based4342,0052,344.63100.0%1,024.0243.7%479.2320.4%841.3835.9%
 Alkylating-agents-based4243,7721,469.59100.0%474.5332.3%433.8129.5%561.2538.2%
 Angiogenesis inhibitors583745,249.94100.0%4,291.4581.7%301.035.7%657.4712.5%
 Taxane-based1721,1232,184.18100.0%1,323.3460.6%409.2218.7%451.6220.7%
 Other3522,9942,458.42100.0%1,552.0363.1%356.3314.5%550.0622.4%
Number of administered IV drugs6
 One9988,0161,855.27100.0%1,007.9154.3%304.2316.4%543.1329.3%
 Two6804,3363,423.98100.0%2,348.0168.6%481.7614.1%594.2117.4%
 Three1611,0492,515.14100.0%1,058.6142.1%693.3627.6%763.1730.3%
 Four471823,372.39100.0%1,771.7852.5%935.9627.8%664.6519.7%

3

CategoryNo. of patientsNo. of monthsTotalIV drugIV administrationOther visit-related services
Average costs ($)%Average costs ($)%Average costs ($)%Average costs ($)%

Total1,2286,025.05,467.61100.0%3,268.4559.8%899.5716.5%1,299.6023.8%
Age
 Less than 25117623.33,476.65100.0%1,442.5041.5%978.1228.1%1,056.0330.4%
 25 to 39152836.25,338.35100.0%3,054.9457.2%1,070.6220.1%1,212.8022.7%
 40 to 543161,513.36,030.91100.0%3,511.1658.2%997.3816.5%1,522.3725.2%
 55 to 643451,650.86,686.45100.0%4,181.9462.5%928.2813.9%1,576.2323.6%
 Greater than 642981,401.44,386.23100.0%2,869.8565.4%623.0914.2%893.2920.4%
Gender2
 Female2891,588.84,544.31100.0%2,712.8859.7%721.3215.9%1,110.1124.4%
 Male2951,563.74,819.57100.0%2,689.1555.8%835.4917.3%1,294.9326.9%
Region
 Midwest2401,040.66,289.83100.0%3,784.4060.2%1,079.8817.2%1,425.5522.7%
 Northeast41207.83,687.44100.0%2,219.6460.2%644.1217.5%823.6722.3%
 South6103,200.94,753.24100.0%2,590.9554.5%830.5917.5%1,331.7028.0%
 Southwest107434.64,106.94100.0%2,531.0061.6%754.7618.4%821.1820.0%
 West2301,141.27,563.95100.0%5,170.1168.4%1,030.2713.6%1,363.5818.0%
Insurance type3
 Managed care6223,088.96,532.36100.0%3,971.3760.8%1,120.5817.2%1,440.4122.1%
 Medicare2831,374.03,764.41100.0%2,374.7363.1%544.9414.5%844.7322.4%
 Medicare HMO24113.43,415.78100.0%1,949.3657.1%534.5615.6%931.8627.3%
 Medicaid67375.71,804.71100.0%722.6140.0%196.0510.9%886.0549.1%
 Medicaid HMO1037.92,716.27100.0%1,281.6647.2%712.0226.2%722.5926.6%
 Indemnity68365.16,232.59100.0%3,853.0461.8%1,051.7916.9%1,327.7621.3%
 Other4154670.06,191.80100.0%3,305.3153.4%991.8616.0%1,894.6330.6%
IV drug (for mSTS)
 Gemcitabine-based4291,577.97,021.77100.0%5,208.7474.2%761.1710.8%1,051.8615.0%
 Anthracycline-based4341,243.03,752.46100.0%1,629.1543.4%768.2420.5%1,355.0736.1%
 Alkylating-agents-based4241,221.54,753.73100.0%1,559.6532.8%1,365.8728.7%1,828.2138.5%
 Angiogenesis inhibitors58321.67,532.36100.0%6,191.3582.2%460.336.1%880.6711.7%
 Taxane-based172575.04,253.79100.0%2,563.9460.3%802.7618.9%887.0820.9%
 Other53521,086.06,006.84100.0%3,755.1362.5%907.7615.1%1,343.9522.4%
Number of administered IV drugs6
 One9982,492.23,950.35100.0%2,105.6953.3%610.2815.4%1,234.3831.2%
 Two6802,781.16,616.14100.0%4,463.7867.5%954.8414.4%1,197.5218.1%
 Three161514.16,725.12100.0%2,888.2342.9%1,631.7924.3%2,205.1032.8%
 Four47237.65,218.13100.0%2,296.0744.0%1,702.7232.6%1,219.3423.4%

1: Treatment costs derived from the contracted allowed payment for a claim.
2: 644 patients were missing gender information.
3: Insurance type is defined at the time of the index mSTS diagnosis.
4: Other includes workers' compensation, Tricare, and self-pay.
5: Gemcitabine-based includes gemcitabine monotherapy and combination therapies. Anthracycline-based includes doxorubicin and epirubicin monotherapies and combination therapies. Alkylating-agents-based includes monotherapies and combination therapies with cisplatin, cyclophosphamide, dacarbazine, etoposide, ifosfamide, temozolomide, and topotecan. Angiogenesis inhibitors include bevacizumab monotherapy. Taxane-based includes docetaxel and paclitaxel monotherapies and combination therapies. Other includes actinomycin D, carboplatin, irinotecan, interferon, oxaliplatin, vincristine, and vinorelbine.
6: Number of mSTS treatments that were administered during the visit.